Why Invivyd, Inc.’s (IVVD) Stock Is Down 5.27%
As of Thursday, October 22, Invivyd, Inc.’s IVVD share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Commentary & Analysis
Why Invivyd, Inc.’s (IVVD) Stock Is Up 6.44%
As of Wednesday, October 21, Invivyd, Inc.’s IVVD share price has surged by 6.44%, which has investors questioning if this is right time to sell.Michael Rose
Why Invivyd, Inc.’s (IVVD) Stock Is Up 5.71%
As of Monday, October 19, Invivyd, Inc.’s IVVD share price has surged by 5.71%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Invivyd, Inc.’s (IVVD) Stock Is Down 6.04%
As of Friday, October 16, Invivyd, Inc.’s IVVD share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Invivyd, Inc.’s (IVVD) Stock Is Up 6.35%
As of Thursday, October 15, Invivyd, Inc.’s IVVD share price has surged by 6.35%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | IVVD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $173.7 | $222.9 | 27% |
|
| Shares Out (Mil) | 320.4 | 53.4 | 83% |
|
| Institutional Ownership | 99.5% | 92.9% | 89% |
|
| Float (Mil) | 207.8 | 40.9 | 74% |
|
| Beta | 0.71 | 0.95 | 41% |
|
| Avg Daily Volume (000s) | 3,709 | 513 | 89% |
|
| Price Change (52-week) |
(69.6%) | 46.3% | 12% |
|
| Growth | IVVD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 4.3% | (10.1%) | 46% |
|
| EPS (5yr) | 60.3% | 15.8% | 96 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (56.4%) | (15.7%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.150) | ($0.570) | ($0.550) | |
| Month Ago EPS | ($0.150) | ($0.570) | ($0.550) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | ($0.130) | ($0.530) | ($0.580) | |
| Year/Year Chg | 7.9% | 86.9% | 57.4% | |
| Financials | IVVD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $58 | $37 | 21% |
|
| Net Income (TTM) (Mil) | ($107) | ($44) | 10% |
|
| EPS (TTM) | ($0.398) | ($1.600) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($108) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $125 | $2 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $61 | $175 | 17% |
|
| Valuation | IVVD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.97 | 2.14 | 24% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IVVD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 92.2% | 66.5% | 94% |
|
| Net Margin | (183.9%) | (75.9%) | 5% |
|
| ROA | (69.7%) | (47.2%) | 8% |
|
| ROE | (95.9%) | (53.5%) | 9% |
|
| Liabilities to Assets | 17.3% | 29.4% | 11% |
|
| F-Score | 3 | 2 | 18% |
|
Invivyd, Inc. did not pass any screens on 10/26/2026.
